Why did Aiforia Technologies stock rise on 8 October?
Written after the close on
Aiforia Technologies +3.79%
Aiforia rose on a PathAI partnership. Aiforia Technologies, listed on Nasdaq Helsinki, rose clearly in the latest session after announcing a commercial agreement with PathAI, a Roche Group company, to place its pathology AI models on PathAI's AISight marketplace, opening access to laboratories in the US and Europe. Over the last five trading days it still fell slightly, and the OMX Helsinki 25 fell slightly too, so the week's direction was set before this news landed. The deal is the likely driver of the latest gain, since it widens distribution of Aiforia's CE-IVD marked (European-certified for clinical diagnostic use) deep-learning tools rather than changing near-term revenue.
Open Aiforia Technologies's chart